Analyst: Lilly doesn't overshadow semaglutide in spite of strong data
![Photo: Sydbank/PR](https://photos.watchmedier.dk/watchmedier/resize:fill:3840:0:0/plain/https://photos.watchmedier.dk/Images/article12807148.ece/ALTERNATES/schema-16_9/doc7ern0mik4zl1q457e0o.jpg)
On Thursday, US pharmaceutical firm Eli Lilly has presented convincing data in favor of the drug candidate tirzepatide, which is a GLP-1 analog.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
Get full access for you and your coworkers
Start a free company trial todayRelated articles
Analyst emphasizes 2021 guidance in Genmab fiscal report
For subscribers